Abstract
OROS® hydromorphone utilizes the Push-Pull™ osmotic delivery system to provide a consistent, 24-hour controlled-release of hydromorphone to patients with chronic pain. The relative beneficial effects of once-daily OROS® hydromorphone and twice-daily controlled-release (CR) morphine on measures of quality of life in patients with chronic cancer pain (oral morphine ≤540 mg/d at enrollment) in a 2-phase, randomized, double-blind, parallel-group trial, are presented. Participants received hydromorphone (12-108 mg/day) or morphine (60-540 mg/day) for up to 24 days (Phase I: IR formulations until dose-stabilized pain control [2-9 days]; Phase II: OROS® hydromorphone or CR morphine for 10-15 days).
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
